Literature DB >> 6112091

Alpha adrenergic blockade by prazosin in therapy of essential hypertension.

C V Ram, R J Anderson, G R Hart, C P Crumpler.   

Abstract

To elucidate the mechanism of action of prazosin in lowering the blood pressure, we studied the vascular pressor responsiveness to the infusion of norepinephrine and angiotensin II before and after prazosin in patients with essential hypertension. After prazosin, the pressor response to the alpha agonist norepinephrine was markedly attenuated, but the vascular reactivity to angiotensin II was unchanged. There was a threefold increment in the dose of norepinephrine required to elicit a 20 mm Hg rise in diastolic blood pressure after prazosin therapy. These results confirm that prazosin induces significant alpha adrenergic blockade during the treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112091     DOI: 10.1038/clpt.1981.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; R L Webb; D Feldman; F Fu; M Beil; L Jin; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

2.  Cardiovascular regulation during administration of co-dergocrine to normal subjects.

Authors:  A Gerber; P Weidmann; K Laederach
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

4.  Alpha-Adrenergic Mechanisms in the Cardiovascular Hyperreactivity to Norepinephrine-Infusion in Essential Hypertension.

Authors:  Lisa-Marie Walther; Roland von Känel; Nadja Heimgartner; Claudia Zuccarella-Hackl; Guido Stirnimann; Petra H Wirtz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.